A.P. Pharma (APPA) Receives 3 Patent Allowances for Lead Candidate APF530

Advanced Cell Technology (ACTC) Receives Data and Safety Monitoring Board Authorization to Proceed with Patient Enrollment

Merge Healthcare (MRGE) Named #1 Vendor Neutral Archive Provider

El Capitan Precious Metals (ECPN) Announces Appointment to Board of Directors

Imogo Mobile Technologies (IMTC) Launches ZaOffice Suite for Tablet Users

American Apparel (APP) Releases Preliminary June and Q2 Sales

Diversinet (DVNTF) Newly Appointed Chairman to Guide alongside CEO Pak

Tegal (TGAL) Appoints James Karis as Co-CEO of the Company

Cytomedix (CMXI) and Possible Partner Extend Exclusivity and Enter Distribution Negotiations

Partnership would bolster AutoloGel System distribution in the U.S. wound care market

CytoSorbents (CTSO) Blood Purification System Data Featured at Western Thoracic Surgical Association

Ohr Pharmaceutical (OHRP) Announces $2.91M Financing through Exercised Series H Warrants

Mass Megawatts Wind Power (MMMW) Begins Construction of New Patent-Based Wind System

Access Pharmaceuticals (ACCP) Presents Positive Data of MuGard Phase 4 Clinical Trial at Cancer Symposium

JWC Acquisition (JWCAU) and The Tile Shop to Form Tile Shop Holdings Venture

Cuticonsai Group of Italy Completes Field Testing of Start Technologies, Inc.’s (GWBU) FEED Device

Independence Energy (IDNGD) Selects First Potential Drill Target in Coleman, Texas

Cellceutix (CTIX) Awarded FDA Approval for Anti-Cancer Compound; Prepares for Phase I Clinical Trial

Synthesis Energy Systems (SYMX) Tests of Turkish Lignite Coals a Success, Syngas Plants Planned

Synthesis Energy Systems reported positive lab-scale output data, with the completion of testing on three Turkish lignite coal targets earmarked for clean coal power generation projects.

OXIS International (OXIS) Announces Online Commercial Availability of Proprietary Joint Health Product

In the company’s news yesterday, OXIS International announced the international commercial launch of its proprietary joint health product, ErgoFlex™, available online.

FDA Approves Cellceutix (CTIX) Proposed Phase I Clinical Trial for Anti-Cancer Compound